BNTC logo

Benitec Biopharma (BNTC)

Profile

Full Name

Benitec Biopharma Inc.

Ticker Symbol

BNTC

Exchange

NASDAQ

Country

United States

IPO

June 24, 2014

Indexes

Not included

Employees

16

Key Details

Price

$13.64(-0.26%)

Market cap

$320.00M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

-

Annual EPS

-$5.51(+60.98% YoY)

PE ratio

-

Next earnings date

May 13, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Apr 10, 25 JMP Securities
Market Outperform
Mar 24, 25 HC Wainwright & Co.
Buy
Mar 18, 25 Citizens Capital Markets
Market Outperform
Feb 21, 25 HC Wainwright & Co.
Buy
Dec 13, 24 Baird
Outperform
Dec 3, 24 Guggenheim
Buy
Jul 22, 24 Leerink Partners
Outperform
Jun 13, 24 Piper Sandler
Overweight
Apr 22, 24 JMP Securities
Market Outperform
Feb 15, 24 JMP Securities
Market Outperform

Institutional Ownership

  • What is the ticker symbol for Benitec Biopharma?
  • Does Benitec Biopharma pay dividends?
  • What sector is Benitec Biopharma in?
  • What industry is Benitec Biopharma in?
  • What country is Benitec Biopharma based in?
  • When did Benitec Biopharma go public?
  • Is Benitec Biopharma in the S&P 500?
  • Is Benitec Biopharma in the NASDAQ 100?
  • Is Benitec Biopharma in the Dow Jones?
  • When was Benitec Biopharma's last earnings report?
  • When does Benitec Biopharma report earnings?
  • Should I buy Benitec Biopharma stock now?

What is the ticker symbol for Benitec Biopharma?

The ticker symbol for Benitec Biopharma is NASDAQ:BNTC

Does Benitec Biopharma pay dividends?

No, Benitec Biopharma does not pay dividends

What sector is Benitec Biopharma in?

Benitec Biopharma is in the Healthcare sector

What industry is Benitec Biopharma in?

Benitec Biopharma is in the Biotechnology industry

What country is Benitec Biopharma based in?

Benitec Biopharma is headquartered in United States

When did Benitec Biopharma go public?

Benitec Biopharma's initial public offering (IPO) was on June 24, 2014

Is Benitec Biopharma in the S&P 500?

No, Benitec Biopharma is not included in the S&P 500 index

Is Benitec Biopharma in the NASDAQ 100?

No, Benitec Biopharma is not included in the NASDAQ 100 index

Is Benitec Biopharma in the Dow Jones?

No, Benitec Biopharma is not included in the Dow Jones index

When was Benitec Biopharma's last earnings report?

Benitec Biopharma's most recent earnings report was on Feb 14, 2025

When does Benitec Biopharma report earnings?

The next expected earnings date for Benitec Biopharma is May 13, 2025

Should I buy Benitec Biopharma stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page